CDK9-IN-2 is a special cyclin-dependent kinase 9 ( CDK9 ) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC 50 of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively. In Vitro CDK9-IN-2 (200 nM) reduces the expression of MEPCE indicating that MEPCE is a pharmacodynamic (PD) marker for any CDK9 inhibitor. The expression of MCL1 protein is reduced 2 hours after treatment and is further reduced after 16 hour exposure to CDK9-IN-2 (500 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid